Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Ball

Allergy & Immunology Mt Pleasant, SC Medical Doctor

NPI 1912909599 CMS profile 177340

180 Wingo Way, Suite 102, Mt Pleasant, SC 29464

Open in the dashboard

General payments

$13,559

592 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Ball of Mt Pleasant, SC is reported in the CMS Open Payments database as having received $13,559 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,904 120
2024 General $1,930 96
2023 General $1,587 77
2022 General $1,613 82
2021 General $2,774 73
2020 General $1,316 72
2019 General $1,435 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Ball
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Bruce Ball were reported at $2,904. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Bruce Ball Allergy & Immunology median Middle half National median
2019 $1,435 $594 $163–$1,512 $163
2020 $1,316 $426 $106–$1,233 $114
2021 $2,774 $638 $157–$1,708 $132
2022 $1,613 $790 $205–$1,961 $149
2023 $1,587 $852 $220–$2,147 $160
2024 $1,930 $865 $203–$2,267 $164
2025 $2,904 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,297 121 payments
  2. Genentech USA, Inc. $1,772 12 payments
  3. CSL Behring $1,434 65 payments
  4. Genzyme Corporation $1,278 52 payments
  5. GlaxoSmithKline, LLC. $1,237 71 payments
  6. Pfizer Inc. $833 43 payments
  7. BioCryst US Sales Co., LLC $702 28 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $650 28 payments
  9. Regeneron Healthcare Solutions, Inc. $455 19 payments
  10. Novartis Pharmaceuticals Corporation $373 18 payments
  11. Other $2,529 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,029 584 payments
  2. Consulting Fee $1,446 4 payments
  3. Education $84 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $1,954 89 payments
  2. Xolair $1,772 12 payments
  3. FASENRA $937 48 payments
  4. Orladeyo $702 28 payments
  5. Haegarda $644 31 payments
  6. NUCALA $636 38 payments
  7. Hizentra $609 24 payments
  8. CUTAQUIG $519 28 payments
  9. PANZYGA $468 25 payments
  10. TEZSPIRE $441 23 payments
  11. Other $6,381 326 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,235

Median for Allergy/ Immunology: 449

Drug cost

$581,595

Median for Allergy/ Immunology: $169,700

Branded share of claims

42.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Haegarda C1 Esterase Inhibitor Brand 11 $378,706
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $55,255
Breo Ellipta Fluticasone/Vilanterol Brand 87 $43,779
Symbicort Budesonide/Formoterol Fumarate Brand 34 $10,976
Qvar Redihaler Beclomethasone Dipropionate Brand 26 $10,225
Arnuity Ellipta Fluticasone Furoate Brand 23 $10,050
Advair Hfa Fluticasone Propion/Salmeterol Brand 16 $8,264
Dulera Mometasone/Formoterol Brand 19 $7,769
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $7,361
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 25 $6,783

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$230,928

Of which drugs: $146,528

Medicare patients

352

Average age 73

Services billed

11,945

244 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 53%
Ischemic heart disease 21%
Osteoporosis 21%
Diabetes 20%
Depression 18%
Atrial fibrillation 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$322 — —
Haegarda
$257 11 —
FASENRA
$161 — —
CUTAQUIG
$128 — —
AIRSUPRA
$117 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record